Classification based on clinical features cannot fully describe biological characteristics, as nearly half of the HER2 negative BC tumors currently defined exhibit some degree of IHC expression, which has recently been renamed as HER2 low expression [21]. This evidence concerns the gene ERBB2 and breast cancer.